PURPOSE Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups. METHODS An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer. Representative index cases of various prostate cancer disease states are presented, including suspected high-risk disease, newly diagnosed treatment-naïve metastatic disease, suspected recurrent disease after local treatment, and progressive disease while undergoing systemic treatment. A systematic review of the literature from 2013 to August 2018 identified fully published English-language systematic reviews with or without meta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared ≥ 2 imaging modalities, and noncomparative studies that reported on the efficacy of a single imaging modality. RESULTS A total of 35 studies met inclusion criteria and form the evidence base, including 17 systematic reviews with or without meta-analysis and 18 primary research articles. RECOMMENDATIONS One or more of these imaging modalities should be used for patients with advanced prostate cancer: conventional imaging (defined as computed tomography [CT], bone scan, and/or prostate magnetic resonance imaging [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or whole-body MRI) according to the clinical scenario.

中文翻译：

---

晚期前列腺癌的最佳成像策略：ASCO 指南

目的 为晚期前列腺癌中影像学的最佳使用提供基于证据和专家的建议。由于对晚期前列腺癌新成像的研究和利用增加，本指南旨在概述可用的技术并提供有关对特定患者亚组适当使用成像的建议。方法 由 ASCO 和腹部放射学会、美国放射学会、核医学和分子影像学会、美国泌尿学会、美国放射肿瘤学会和泌尿肿瘤学会的成员召集专家小组进行系统评价文献，并制定关于晚期前列腺癌影像学最佳使用的循证指南。介绍了各种前列腺癌疾病状态的代表性指标病例，包括疑似高危疾病、新诊断初治转移性疾病、局部治疗后疑似复发性疾病和接受全身治疗时进展性疾病。对 2013 年至 2018 年 8 月的文献进行的系统评价确定了有或没有荟萃分析的完全发表的英文系统评价、严格进行的 III 期随机对照试验的报告，这些试验比较了 ≥ 2 种成像方式，以及报告疗效的非比较研究单一成像模式。结果 共有 35 项研究符合纳入标准并形成证据基础，其中包括 17 项系统评价（有或没有荟萃分析）和 18 篇主要研究文章。